Eosinophilic Esophagitis (EoE)

The AJMC® Eosinophilic Esophagitis compendium is a comprehensive resource for clinical news and expert insights for the chronic immune system disease.

Dr David R. Stukus on Eosinophilic Esophagitis Guidelines and the Pattern of Disease

January 24th 2022, 8:15pm

Video

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses guidelines for eosinophilic esophagitis, as well as some disease patterns that may occur.

For Some Toddlers, Oral Immunotherapy Led to Remission for Peanut Allergy

January 20th 2022, 11:30pm

Article

For the first time, a major study showed that remission for peanut allergy can be achieved even in very young children using oral immunotherapy.

Analysis Shows Small Rate of Eosinophilic Esophagitis in Peanut Immunotherapy Trial

January 15th 2022, 12:15pm

Article

The eosinophilic esophagitis responded to treatment or resolved after the peanut oral immunotherapy stopped.

Dr David R. Stukus on the Increase in Eosinophilic Esophagitis

January 6th 2022, 10:15pm

Video

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, talks about the increase of eosinophilic esophagitis, or EoE, along with other allergic conditions.

Guideline-Informed Care Among Medicaid-Enrolled Children With Food Allergy

December 11th 2020, 2:00pm

Article

This article describes food allergy–related service utilization and identifies factors associated with guideline-informed care among Medicaid-enrolled US children with food allergy.

OIT or OIT Plus Biologic? Allergists, Patients Look to Lessen Food Allergy Woes

November 3rd 2018, 1:25am

Article

Avoid the allergen. For decades, that was the only advice for people with life threatening food allergies. While that is still true, the food allergy community is cautiously, but excitedly, watching research unfold that could help patients tolerate more of the allergen that might otherwise have serious or deadly consequences.

Eczema Drug Shows Promising Phase 2 Results for Treatment of Eosinophilic Esophagitis

October 17th 2017, 6:26am

Article

Dupilumab's effectiveness is due to the monoclonal antibody's ability to rapidly reduce inflammation.